FDMT / 4D Molecular Therapeutics Presents Interim Results from the Ongoing 4D-125 Phase 1/2 Clinical Trial in Patients with Advanced X-linked Retinitis Pigmentosa at the ASRS Annual Meeting

4D Molecular Therapeutics, Inc. has faced setbacks, with the FDA placing a clinical hold on its Fabry Disease program due to serious kidney conditions more_horizontal

4D Molecular Therapeutics demonstrates a robust economic position and promising line-up of gene therapies, with a commitment to innovation and strateg more_horizontal

Shares of "directed evolution" genetic medicine concern 4D Molecular Therapeutics, Inc. have more or less hovered near $20 since positive 4D-150 data more_horizontal

Viking Global Investors LP, the firm managed by Andreas Halvorsen (Trades, Portfolio), disclosed in a regulatory filing that it boosted its holding in more_horizontal

4D Molecular Therapeutics, Inc. (FDMT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ear more_horizontal

4D Molecular Therapeutics, Inc. (FDMT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings esti more_horizontal

With its strong focus on product design and development excellence, as evidenced by its sustained success in IND clearance, 4D Molecular Therapeutics more_horizontal

4D Molecular Therapeutics, Inc. (FDMT) delivered earnings and revenue surprises of -12% and 74.90%, respectively, for the quarter ended December 2022. more_horizontal